Idorsia Ltd
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the… Read more
Idorsia Ltd (IDRSF) - Net Assets
Latest net assets as of September 2025: $-1.13 Billion USD
Based on the latest financial reports, Idorsia Ltd (IDRSF) has net assets worth $-1.13 Billion USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($454.01 Million) and total liabilities ($1.59 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-1.13 Billion |
| % of Total Assets | -249.77% |
| Annual Growth Rate | N/A |
| 5-Year Change | -307.03% |
| 10-Year Change | N/A |
| Growth Volatility | 305.31 |
Idorsia Ltd - Net Assets Trend (2016–2024)
This chart illustrates how Idorsia Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Idorsia Ltd (2016–2024)
The table below shows the annual net assets of Idorsia Ltd from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-1.21 Billion | -25.13% |
| 2023-12-31 | $-968.72 Million | -46.56% |
| 2022-12-31 | $-660.96 Million | -734.29% |
| 2021-12-31 | $104.20 Million | -82.20% |
| 2020-12-31 | $585.48 Million | +256.25% |
| 2019-12-31 | $164.35 Million | -75.01% |
| 2018-12-31 | $657.62 Million | -11.07% |
| 2017-12-31 | $739.51 Million | +45.58% |
| 2016-12-31 | $507.97 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Idorsia Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 307163300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $9.49 Million | % |
| Other Comprehensive Income | $2.86 Million | % |
| Other Components | $2.18 Billion | % |
| Total Equity | $-1.21 Billion | 100.00% |
Idorsia Ltd Competitors by Market Cap
The table below lists competitors of Idorsia Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shandong Weigao Orthopaedic Device Co. Ltd. A
SHG:688161
|
$171.85 Million |
|
Capital Futures Corp
TW:6024
|
$171.88 Million |
|
Chunbo Co. Ltd
KQ:278280
|
$171.96 Million |
|
ADCNF
OTCGREY:ADCNF
|
$172.01 Million |
|
ECHO INVESTMENT ZY 005
F:4I3
|
$171.78 Million |
|
Bohai Water Industry Co Ltd
SHE:000605
|
$171.74 Million |
|
29METALS Ltd
AU:29M
|
$171.73 Million |
|
Mahindra Logistics Limited
NSE:MAHLOG
|
$171.72 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Idorsia Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -968,718,000 to -1,212,145,000, a change of -243,427,000.
- Net loss of 263,757,000 reduced equity.
- Share repurchases of 80,000 reduced equity.
- Other comprehensive income decreased equity by 6,884,000.
- Other factors increased equity by 27,294,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-263.76 Million | -21.76% |
| Share Repurchases | $80.00K | -0.01% |
| Other Comprehensive Income | $-6.88 Million | -0.57% |
| Other Changes | $27.29 Million | +2.25% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Idorsia Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $4.24 | $1.05 | x |
| 2017-12-31 | $6.45 | $1.05 | x |
| 2018-12-31 | $5.26 | $1.05 | x |
| 2019-12-31 | $1.30 | $1.05 | x |
| 2020-12-31 | $4.10 | $1.05 | x |
| 2021-12-31 | $0.62 | $1.05 | x |
| 2022-12-31 | $-3.73 | $1.05 | x |
| 2023-12-31 | $-5.43 | $1.05 | x |
| 2024-12-31 | $-6.64 | $1.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Idorsia Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -234.43%
- • Asset Turnover: 0.22x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-121.85%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -65.42% | 0.00% | 0.00x | 1.79x | $-386.37 Million |
| 2017 | -1.91% | -9.03% | 0.12x | 1.73x | $-88.81 Million |
| 2018 | -58.13% | -637.42% | 0.04x | 2.12x | $-452.86 Million |
| 2019 | -286.24% | -2072.33% | 0.02x | 5.82x | $-510.85 Million |
| 2020 | -75.97% | -619.85% | 0.05x | 2.45x | $-503.34 Million |
| 2021 | -608.99% | -1795.23% | 0.02x | 14.23x | $-645.02 Million |
| 2022 | 0.00% | -852.60% | 0.11x | 0.00x | $-761.80 Million |
| 2023 | 0.00% | -195.50% | 0.30x | 0.00x | $-201.05 Million |
| 2024 | 0.00% | -234.43% | 0.22x | 0.00x | $-142.54 Million |
Industry Comparison
This section compares Idorsia Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Idorsia Ltd (IDRSF) | $-1.13 Billion | -65.42% | N/A | $171.80 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |